0 Items
Select Page

Tick-Borne Encephalitis

Tick-borne encephalitis virus (TBEV) causes 13,000 cases of human meningitis and encephalitis annually. Mortality varies depending on the sub-type, but long-term neuropsychiatric disorders can occur in a significant proportion of patients.

The Native Antigen Company offers recombinant TBEV proteins developed from our proprietary mammalian expression system alongside monoclonal antibodies and immunoassays.

TBEV Background

Tick-borne Encephalitis virus (TBEV) is primarily transmitted through the bite of infected hard ticks, of the family Ixodidae. Small rodents are the primary hosts for TBEV, with humans acting as accidental hosts. The virus can also be transmitted to humans through unpasteurized milk in areas where TBEV is prevalent (CDC).

TBEV is a neurotrophic virus that causes tick-born encephalitis (TBE) in humans, affecting the central nervous system (CNS). TBE is endemic in many parts of Europe, China, Mongolia and the Russian Federation, and is the most common tick-borne CNS infection in these areas (WHO). Three subtypes of TBEV have been recognised that cause TBR, which are European, Far-Eastern and Siberian.

TBEV infection is asymptomatic in most cases with some individuals presenting with influenza-like symptoms. In symptomatic cases, TBEV infection typically presents as meningitis, encephalitis or meningoencephalitis. A high percentage of acute TBE cases may also develop post-encephalitic syndrome with long-lasting neuropsychiatric symptoms or neurological dysfunction (Bogovic, P).

Diagnosis of TBE infection is primarily based on clinical presentation and serological testing for TBEV-specific IgM and IgG antibodies in patient sera and cerebrospinal fluid. There is no anti-viral treatment for TBEV. However, several effective vaccines for TBEV are currently available which are based on European and Far-Eastern strains of the virus (WHO).

Tick-Borne Encephalitis Antigens

The Native Antigen Company prepares recombinant TBEV proteins in its proprietary mammalian cell expression system, including highly pure NS1 protein, in its glycosylated and predominantly hexameric format.

Tick-Borne Encephalitis Antibodies

The Native Antigen Company is pleased to offer a full panel of monoclonal antibodies to TBEV antigens, which are suitable for the development of specific immunoassays. These antibodies have been tested against our renowned mammalian-expressed, recombinant proteins, and are suitable for use in both ELISA and Western blot applications.

 

Tick-Borne Encephalitis Immunoassays

We are pleased to offer ELISA assays for the detection of antibody response (IgG and IgM) to Tick-borne encephalitis virus. These assays are suitable for use in laboratory research and development activities and vaccine research studies.

Questions?

Check out our FAQ section for answers to the most frequently asked questions about our website and company.

A Q&A with David Flavell of Leukaemia Busters

In this blog, we speak with Dr. David Flavell about his scientific career, the legacy of Leukaemia Busters, and the recent impact that COVID-19 has had on his research.Tell me about your scientific background David. I was born in a seaside town called Southport in...

Avoiding the Immunopathology Pitfalls of a COVID-19 Vaccine

In the second of a three-part series on COVID-19 vaccines, we explore the potential challenges in stimulating safe vaccine responses and outline the role that diagnostics will play in guiding their development.Rogue Responses Antibodies play a crucial role in...

The Bumpy Road to a Cytomegalovirus Vaccine

The development of a cytomegalovirus vaccine has been 50 years in the making. Are there any technologies in the pipeline that could prompt a breakthrough? This article was originally posted online at The Medicine Maker, a Texere publication.To say that...

Why We Need Antigen and Antibody Tests for COVID-19

RT-PCR is the workhorse of viral diagnosis and has been invaluable in COVID-19 case confirmation and isolation guidance. However, while fast and sensitive, PCR suffers from some inherent drawbacks that limit it to diagnosis during the acute phase of infection. To...

Gonorrhea: What’s Currently in the Clinical Pipeline?

This article was written by our friends at Infectious Diseases Hub, a free-to-access website that aims to deliver up-to-date, essential research and information on all aspects of microbiology, virology, mycology and parasitology – from bench to bedside....

Get in Touch

We sometimes send exclusive information and offers to our customers - please let us know if you are happy to receive these

1 + 7 =

Live Customer Feedback

Join our mailing list

* indicates required